Latest filing published 07 Nov 2016 for Ernexa Therapeutics Inc., €45k.
Insider track record
Closed purchases
Based on 13 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -41.2%Entry US$153,450.00 · Close at T+365 US$90,300.00
- +21.5%Entry US$73,350.00 · Close at T+365 US$89,100.00
- -5.5%Entry US$97,500.00 · Close at T+365 US$92,100.00
- -21.2%Entry US$127,500.00 · Close at T+365 US$100,500.00
- -25.9%Entry US$142,500.00 · Close at T+365 US$105,600.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Dave Brian Miller: trading record in brief
Dave Brian Miller is a declared insider of Ernexa Therapeutics Inc., with filings sourced from SEC (Form 4). In total, 14 filings cover trades dated from 17 May 2016 to 4 November 2016.
No open-market sale appears; the market trades are 13 purchases worth €26k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant.
In size, the median ticket on the buying side is €1,542. Clusters matter here: 9 out of 13 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 13 purchases with a full 90-day history, the hit rate stands at 38% and the median 90-day move at -23.9%. This is a record of the past, not a forecast.
The latest filing, published on 7 November 2016, reports a share grant of €45k in Ernexa Therapeutics Inc. The clock since the last published purchase (20 June 2016) now reads 3,794 days. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Dave Brian Miller
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,531 shares@ US$6.6463.3% of flowCommon StockSEC:0001493152-16-014601:0
- 1,000 shares@ US$4.725.9% of flowCommon StockSEC:0001493152-16-010950:0Canonical exit: 15 Sept 2016 (T+90)
- 500 shares@ US$4.783.0% of flowCommon StockSEC:0001493152-16-010950:1Canonical exit: 15 Sept 2016 (T+90)
- 500 shares@ US$4.793.0% of flowCommon StockSEC:0001493152-16-010950:2Canonical exit: 15 Sept 2016 (T+90)
- 10,000 shares@ US$0.1141.4% of flowCommon StockSEC:0001493152-16-010908:0Canonical exit: 13 Sept 2016 (T+90)
- 10,000 shares@ US$0.121.5% of flowCommon StockSEC:0001493152-16-010908:1Canonical exit: 13 Sept 2016 (T+90)
- 10,000 shares@ US$0.11441.4% of flowCommon StockSEC:0001493152-16-010908:2Canonical exit: 14 Sept 2016 (T+90)
- 10,000 shares@ US$0.1181.5% of flowCommon StockSEC:0001493152-16-010908:3Canonical exit: 14 Sept 2016 (T+90)
- 30,000 shares@ US$0.124.4% of flowCommon StockSEC:0001493152-16-010692:0Canonical exit: 6 Sept 2016 (T+90)
- 20,000 shares@ US$0.164.0% of flowCommon StockSEC:0001493152-16-010438:0Canonical exit: 22 Aug 2016 (T+90)
- 20,000 shares@ US$0.16694.1% of flowCommon StockSEC:0001493152-16-010067:0Canonical exit: 15 Aug 2016 (T+90)
- 10,000 shares@ US$0.172.1% of flowCommon StockSEC:0001493152-16-010067:1Canonical exit: 15 Aug 2016 (T+90)
- 10,000 shares@ US$0.1652.1% of flowCommon StockSEC:0001493152-16-010067:2Canonical exit: 15 Aug 2016 (T+90)
- 10,000 shares@ US$0.17452.2% of flowCommon StockSEC:0001493152-16-010067:3Canonical exit: 15 Aug 2016 (T+90)
14 of 14 declarations
